Evidence map›Paper›PMID 36032811›Full record

ArticleGynecologic oncology reports2022

Recurrent uterine inflammatory myofibroblastic tumor previously managed as leiomyosarcoma has sustained response to alectinib.

Erica V Carballo, Tra V Pham, Gulisa Turashvili, Krisztina Hanley, Kristen D Starbuck, Jane L Meisel

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Leiomyosarcoma of lower urinary tract: Literature review.Central European journal of urology · 2025
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Erica V CarballoDivision of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine, United States.
Tra V PhamDivision of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine, United States.
Gulisa TurashviliDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, United States.
Krisztina HanleyDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, United States.
Kristen D StarbuckDivision of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine, United States.
Jane L MeiselDivision of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Soft tissue sarcomas encompass a wide range of histologic subtypes with varied clinical implications. The incorporation of comprehensive genetic profiling into clinical practice is refining our ability to make these distinctions in diagnosis to better reflect prognosis and clinical behavior of a tumor. In this report, we describe a case of recurrent inflammatory myofibroblastic tumor (IMT) of the uterus, initially diagnosed and managed as leiomyosarcoma. At the time of recurrence, the patient was found to have a

Indexed as

ALK fusionALK-inhibitorCase reportTNS1-ALK fusionUterine inflammatory myofibroblastic tumorUterine leiomyosarcoma

Identifiers

PMID36032811
PMCPMC9403501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.